Article type: Decision-support guide
Scope: Children and adolescents after autism diagnosis; U.S. clinical genetics context
Last updated: July 18, 2026
Genetic testing is not an autism test
There is no single genetic test that confirms autism or rules it out.
Autism is diagnosed clinically, based on developmental history and behavior. Genetic testing asks a different question: is there a genetic condition or variant that helps explain a child's broader developmental or medical profile?
That distinction matters. A positive result does not explain the whole child. A negative result does not mean autism is not biological. A variant of uncertain significance is not an answer parents should be left to interpret alone.
Testing can be useful. It can also be confusing, expensive, emotionally loaded, and dependent on the child's full presentation.
What testing may find
Genetic testing may identify:
- a pathogenic or likely pathogenic variant;
- a chromosome deletion or duplication;
- Fragile X syndrome;
- a syndrome associated with autism, developmental delay, intellectual disability, seizures, congenital differences, or other medical features;
- a variant of uncertain significance;
- no reportable finding.
It may also raise family questions because genetic information can involve parents, siblings, future pregnancies, and unexpected findings.
Tests families may hear about
Chromosomal microarray
Chromosomal microarray looks for missing or extra pieces of chromosomes, often called copy-number changes. ACMG-related technical standards describe chromosomal microarray as a first-tier approach for people with developmental delay, intellectual disability, autism spectrum disorder, and/or multiple congenital anomalies.
Fragile X testing
Fragile X syndrome requires a specific FMR1 DNA test. CDC states that Fragile X cannot be diagnosed using a standard chromosome test or microarray. CDC also says any child with unexplained developmental delay, intellectual disability, and/or autism spectrum disorder should receive genetic testing for Fragile X syndrome.
Exome or genome sequencing
Exome and genome sequencing look more broadly at genetic code. ACMG guidance strongly recommends considering exome or genome sequencing as a first- or second-tier test for children with congenital anomalies, developmental delay, or intellectual disability. That does not mean every child with isolated autism has the same testing pathway. The child's broader profile matters.
Targeted testing
If the child has specific features, family history, seizures, unusual growth, congenital differences, regression, or a known syndrome suspicion, a clinician may recommend targeted testing or referral to genetics.
Why the broader profile matters
Testing decisions may differ when autism occurs with:
- intellectual disability;
- global developmental delay;
- seizures;
- congenital anomalies;
- unusual growth pattern;
- motor regression;
- family history;
- dysmorphic features;
- significant medical problems;
- known syndrome features.
Parents should ask why a specific test is being recommended for this specific child.
What a result may change
A useful result may affect:
- medical monitoring;
- referrals;
- seizure, heart, kidney, vision, hearing, or other surveillance in certain syndromes;
- family testing;
- recurrence counseling;
- access to condition-specific communities;
- research eligibility;
- explanation of associated risks;
- school or service documentation in some cases.
It may not change day-to-day autism supports. A child still needs communication access, school supports, therapies, accommodations, and family support based on actual needs.
What testing usually cannot predict
Genetic testing usually cannot precisely predict:
- future speech;
- independence;
- personality;
- exact support needs;
- response to therapy;
- school outcome;
- every medical complication;
- the complete cause of autism.
Even when a genetic finding is real, development remains individual.
Result categories parents should understand
Pathogenic or likely pathogenic
This means the lab believes the finding is disease-causing or very likely disease-causing. A genetics professional should explain what it does and does not mean.
Negative
No reportable result was found. This does not rule out genetic contribution.
Variant of uncertain significance
A VUS is a finding whose meaning is not yet clear. It should not be treated as a confirmed cause without expert interpretation. It may be reclassified later.
Secondary or incidental finding
Some tests can find information unrelated to autism, such as risk for other conditions. Families should understand what may be reported before testing.
Questions for genetics appointments
- Why is this test being recommended?
- What can it detect?
- What can it miss?
- Does it look for Fragile X?
- Will parents need testing too?
- What result types could we receive?
- Are secondary findings reported?
- What could change medically if a result is found?
- What will insurance cover?
- Where will the data be stored?
- Who will explain the result?
- Can uncertain results be reanalyzed later?
Direct-to-consumer caution
Direct-to-consumer genetic products are not substitutes for clinical genetics evaluation. They may not test the right thing, may not interpret developmental findings properly, and may leave families with anxiety instead of a medical plan.
If the question is autism, developmental delay, seizures, regression, or family recurrence, involve a clinician or genetic counselor.
References and further reading
Clinical genetics and autism
- CDC. Genetic Testing. General overview of genetic testing and why counseling matters.
- CDC. Healthcare Providers: Top 5 Things to Know About Fragile X Syndrome. Fragile X testing and FMR1-specific test details.
- Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability. Genetics in Medicine. 2021.
- Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for interpretation and reporting of constitutional copy-number variants. Genetics in Medicine. 2020.
- Manning M, Hudgins L. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision. Genetics in Medicine. 2021.
- American Academy of Pediatrics. The Role of Genetic Testing Among Autistic Individuals. Pediatrics. 2022.
Editorial notes
This article is educational and does not recommend a specific test for a specific child. Clinical geneticist and certified genetic counselor review is recommended before live publication.
